Atezolizumab and bevacizumab for non-resectable or metastatic combined hepatocellular-cholangiocarcinoma: A multicentric retrospective study.
Elia GiganteMohamed BouattourJosé Ursic BedoyaHélène RegnaultMarianne ZiolEric AssenatValérie ParadisJulien CalderaroNathalie Ganne-CarriéKarine Bouhier-LeporrierGiuliana AmaddeoJean Charles NaultPublished in: United European gastroenterology journal (2023)
The combination of atezolizumab and bevacizumab showed signs of anti-tumor efficacy in patients with unresectable/metastatic cHCC-CCA.